1. Date of download: 5/29/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Adjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With Resected Pancreatic Cancer: The CONKO-001 Randomized Trial JAMA. 2013;310(14):1473-1481. doi:10.1001/jama.2013.279201 Study FlowThe number of patients screened for enrollment in the study was not documented. Figure Legend:

2. Date of download: 5/29/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Adjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With Resected Pancreatic Cancer: The CONKO-001 Randomized Trial JAMA. 2013;310(14):1473-1481. doi:10.1001/jama.2013.279201 Kaplan-Meier Estimates of Disease-Free and Overall SurvivalA, Median disease-free survival was 13.4 months (95% CI, 11.6-15.3 months) in the gemcitabine group compared with 6.7 months (95% CI, 6.0-7.5 months) in the observation group (hazard ratio, 0.55 [95% CI, 0.44-0.69]). B, Median overall survival was 22.8 months (95% CI, 18.5-27.2 months) in the gemcitabine group compared with 20.2 months (95% CI, 17.7-22.8 months) in the observation group (hazard ratio, 0.76 [95% CI, 0.61-0.95]). Vertical lines on curves indicate patients censored on the date of their last follow-up. Figure Legend:

3. Date of download: 5/29/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Adjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With Resected Pancreatic Cancer: The CONKO-001 Randomized Trial JAMA. 2013;310(14):1473-1481. doi:10.1001/jama.2013.279201 Disease-Free and Overall SurvivalSize of data markers indicates the amount of statistical information in the respective subgroup. Figure Legend: